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Abstract
Our study has shown that the Amaryllidaceae iso-
carbostyril narciclasine induces marked apoptosis-
mediated cytotoxic effects in human cancer cells but
not in normal fibroblasts by triggering the activation of
the initiator caspases of the death receptor pathway
(caspase-8 and caspase-10) at least in human MCF-7
breast and PC-3 prostate carcinoma cells. The formation
of the Fas and death receptor 4 (DR4) death-inducing
signaling complex was clearly evidenced in MCF-7 and
PC-3 cancer cells. Caspase-8 was found to interact with
Fas and DR4 receptors on narciclasine treatment. How-
ever, narciclasine-induced downstream apoptotic path-
ways in MCF-7 cells diverged from those in PC-3 cells,
where caspase-8 directly activated effector caspases
such as caspase-3 in the absence of any further release
of mitochondrial proapoptotic effectors. In contrast, in
MCF-7 cells, the apoptotic process was found to require
an amplification step that is mitochondria-dependent,
with Bid processing, release of cytochrome c, and
caspase-9 activation. It is postulated that the high se-
lectivity of narciclasine to cancer cells might be linked,
at least in part, to this activation of the death recep-
tor pathway. Normal human fibroblasts appear approxi-
mately 250-fold less sensitive to narciclasine, which
does not induce apoptosis in these cells probably due
to the absence of death receptor pathway activation.
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Introduction
Cancer cells have an inbuilt urge to survive, so that any
genetic change that favors survival against adverse con-
ditions will be selected [1–3]. As a consequence, some
tumors will survive exposure to even the most potent ther-
apeutic agents [1–3].
Today, a large number of drugs used to fight cancer are
proapoptotic. The majority of proapoptotic cytotoxic drugs
currently used to treat cancer patients take advantage of
cell division itself in an attempt to achieve selective action,
based on the more rapid division of cancer cells compared to
their normal counterparts [4]. However, major problems with
these molecules persist because they are not sufficiently se-
lective for cancer cells, resulting in toxicity to normal cells and
provoking widespread and serious consequences in patients
[4]. Therefore, the need to identify potent anticancer agents
that target tumor cells more selectively remains.
Plants of the Amaryllidaceae family have long been known
for their toxicity and medicinal properties. For instance, oil from
the daffodil Narcissus poeticus L. was employed as treatment
for cancer-related diseases in ancient Greece [5]. Among the
many compounds isolated from Amaryllidaceae, hydroxylated
phenantridones, also referred to as Amaryllidaceae isocarbo-
styrils, have long been under scrutiny due to their promising anti-
tumor activity. Narciclasine (Figure 1A) was first isolated from
several varieties of narcissus in 1967 [6]. Seventeen years later
in 1984, pancratistatin (Figure 1A) was purified from the bulbs
of Pancratium littorale (also known as Hymenocallis littoralis;
Figure 1A [7]). Little is known of the mechanism of action of this
family of compounds. Narciclasine was originally described
as antimitotic and as displaying colchicine-like effects [6]. It
was also found to be an inhibitor of peptide bond formation in
eukaryotic ribosomes, given its ability to bind to the 60S ribo-
somal subunit and more precisely to the peptidyl-transferase
center [8,9]. Furthermore, unlike many other anticancer drugs,
narciclasine has been found not to interact or form a complex
with DNA [10]. More recently, McLachlan et al. [11] demon-
strated that pancratistatin, whose chemical structure is very
close to that of narciclasine (Figure 1A), induced rapid apop-
tosis in SHSY-5Y neuroblastoma cells, accompanied by disrup-
tion of mitochondrial membrane potential DWm. Additionally, a
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decrease in ATP synthesis and an increase in the production
of reactive oxygen species, which are indicative of a dysfunc-
tion of the mitochondrial respiratory chain, were observed in
intact mitochondria incubated with the molecule [11]. Narci-
clasine and pancratistatin also emerged as interesting anti-
tumor drugs in the National Cancer Institute database (http://
dtp.nci.nih.gov/), with convincing in vivo data obtained in sev-
eral mouse cancer models. The present study thus aims to
characterize the mechanism of action of narciclasine when
used at 1 mM in vitro in human normal versus cancer cell lines.
Materials and Methods
Narciclasine Isolation
Fresh bulbs of Narcissus pseudonarcissus Carlton (500 g)
were homogenized, and ethanol (1 l) was added. The mixture
was stirred at room temperature for 24 hours. After filtration,
residue was resuspended in ethanol for 2 hours and filtered
again. The two filtrates were combined, and ethanol was
removed under reduced pressure to leave a residual essen-
tially aqueous extract of 200 ml. This was first extracted
thrice with CH2Cl2 and then thrice with ethyl acetate. The
combined ethyl acetate extracts were concentrated under
reduced pressure to obtain 600 mg of the residue that was
dissolved and subsequently applied to a silica gel chro-
matography column (particle size distribution: 40–63 mm)
and eluted first with CH2Cl2 and then with CH2Cl2/MeOH
(9:1). The solid residue (100 mg) obtained (Rf = 0.6 CH2Cl2/
MeOH, 8:2) was then crystallized in methanol to obtain 46 mg
of narciclasine (overall yield: 0.009%). The structure of narci-
clasine was confirmed after detailed analyses of 1H, 13C,
distortionless enhanced polarization transfer, correlation spec-
troscopy, heteronuclear multiple quantum correlation nuclear
magnetic resonance spectra, and mass spectra, and by com-
parisons with literature data.
Cell Lines and Culture Conditions
Cell lines were purchased from the American Type Cul-
ture Collection (ATCC; Manassas, VA). Culture media, sup-
plements, and trypsin–EDTA solution were obtained from
Gibco-BRL/Invitrogen (Merelbeke, Belgium). Fetal bovine
serum (FBS) was inactivated before use by heating for 1 hour
at 56jC. Cells were cultured at 37jC in Falcon tissue culture
dishes (Nunc Invitrogen, Merelbeke, Belgium) in an incubator
containing a 5% CO2 humidified atmosphere. The MCF-7
breast (ATCC; HTB-22) and PC-3 prostate cancer (ATCC;
CRL-1435) cell lines were cultivated in RPMI 1640 (Gibco-
BRL/Invitrogen; cat. no. 52400-025); the MDA-MB-231 breast
cancer cell line (ATCC; HTB-26) was cultivated in DMEM–
F12 (Gibco-BRL/Invitrogen; cat. no. 31330-03); and the
normal human fibroblast cell line Ccd-25-Lu (ATCC; CCL-
215) was cultivated in BME (Gibco-BRL/Invitrogen; cat. no.
41010-026). Culture media were supplemented with 10%
FBS, 200 IU/ml penicillin, 200 IU/ml streptomycin, and
0.1 mg/ml gentamicin. In addition to cancer cell lines MCF-
7 and PC-3 and the normal human fibroblast cell line Ccd-
25-Lu, normal human fibroblasts WI-38 (ATCC; CCL-75)
and WS-1 (ATCC; CRL-2029) and human cancer cell lines
pancreatic BxPC-3 (ATCC; CRL-1687), glioblastoma U-373
(ATCC; HTB-17), non–small cell lung cancer (NSCLC) A549
(ATCC; CCL-185), and colon carcinoma LoVo (ATCC; CCL-
229) were specifically used in MTT (3-[4,5-dimethylthiazol-2yl]-
diphenyltetrazolium bromide) assays, as described below.
Determination of Cytotoxicity In Vitro
The effects of narciclasine on the overall proliferation rate/
cytotoxicity of cancer and normal cells lines in vitro were
determined using colorimetric MTT (Sigma-Aldrich, Bornem,
Belgium) assay, as previously described [12,13]. Briefly, cells
seeded in 96-well culture plates were treated for 72 hours
with different concentrations of narciclasine ranging from
1 nM to 10 mM, with semilog concentration increasing. The
yellow MTT product is converted to a blue formazan deriva-
tive through mitochondrial enzymatic reduction. At the end
of the incubation, blue formazan is solubilized with DMSO,
and absorbance at 570 nm, which is directly proportional to
Figure 1. Structure and cytotoxic activity of narciclasine. (A) Chemical struc-
ture of narciclasine and pancratistatin. (B) Effect of narciclasine on the overall
survival of normal and tumor cells. The cytotoxic activity of narciclasine was
analyzed using MTT assay, as described in the Materials and Methods section.
Six tumor cells lines were tested: PC-3 prostate carcinoma, U-373 glioma,
MCF-7 breast carcinoma, BxPC-3 pancreatic cancer, A-549 NSCLC, and LoVo
colon cancer. To determine the selectivity of narciclasine for cancer cells, a
panel of three normal human fibroblast cell lines was used: WI-38, WS-1, and
Ccd-25-LU cells. (C) Cells were incubated with narciclasine for 72 hours at
concentrations ranging from 1 nM to 10 M, with semilog concentration in-
creasing. Top graph: The effect of narciclasine on each individual cell line.
Bottom graph: The mean activity of narciclasine against the six tumor cell lines
compared to the mean of the three normal cell lines.
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the number of living cells, is determined. Experiments were
carried out in sextuplicate.
Mitochondrial Membrane Potential (DWm) Determination
DWm was monitored using the DWm-specific cationic li-
pophilic dye JC-1 (Calbiochem; cat. no. 420200, Nottingham,
UK) and flow cytometry. JC-1 staining was undertaken ac-
cording to a previously published method [14,15], with minor
modifications. Briefly, following treatment with narciclasine,
cells were harvested and cell density was determined. One
million cells were stained for 10 minutes in 1 ml of cul-
ture medium containing 10% FBS and 10 mg/ml JC-1. Cells
were washed once with 10 ml of ice-cold PBS and, after
centrifugation, resuspended in 1 ml of ice-cold PBS. Analy-
sis was performed immediately on an Epics XL.MCL flow
cytometer (Beckman Coulter; Analis, Suarle´e, Belgium)
equipped with a 488-nm argon laser. Each acquisition in-
cluded 10,000 events. Cells with an intact DWm show high
red fluorescence (channel 2, FL2). Loss of DWm is visualized
by a drop in the red fluorescence corresponding to mito-
chondrial JC-1 aggregates. Green fluorescence (channel 1,
FL1) is the result of monomeric cytoplasmic JC-1. To per-
form an analysis by fluorescence microscopy, cells were
seeded in six-well plates at 30,000 cells/well. On the next
day, cells were incubated with and without narciclasine (0.1–
1 mM) for 18 hours. At the end of the incubation, the cells were
stained with 10 mg/ml JC-1 for 15 minutes at 37jC and then
washed twice with PBS before immediate analysis on a
fluorescence microscope.
Preparation of Mitochondria and Determination of
Cytochrome c Release
Mitochondria were purified using a differential centrifuga-
tion method, as previously described [16,17]. Briefly, cells
were harvested, centrifuged at 500g for 5 minutes at 4jC, and
resuspended in fractionation buffer A (10 mM Hepes pH 7.4,
0.1 mM EDTA, 1 mM EGTA, and 250 mM sucrose) sup-
plemented with protease inhibitors. Cell disruption was per-
formed mechanically by passing the cells through a 23-gauge
needle 5 to 10 times. Homogenates were centrifuged twice
at 700g for 10 minutes at 4jC to remove intact cells, lysed
membranes, and nuclei. Supernatants were then further cen-
trifuged at 7000g for 20 minutes at 4jC to pellet the mito-
chondria. The supernatants (cytosolic fraction) were kept for
analysis. The pellets containing the mitochondria were re-
suspended in fractionation buffer B (10 mM Hepes pH 7.4,
5 mM KH2PO4, 5 mM succinate, and 250 mM sucrose) and
centrifuged at 10,000g for 15 minutes. The resulting purified
mitochondria were then resuspended in fractionation buffer
B at a final protein concentration of 2 to 3 mg/ml. For com-
plete lysis of mitochondria before Western blot analysis,
preparations were incubated overnight at 80jC. As pro-
cess controls, Western blot analyses were performed to
measure the levels of GRP75 (Santa Cruz Biotechnology,
Santa Cruz, CA), cytochrome c (cyt c; BD Pharmingen,
Erembodegem, Belgium), and proliferating cell nuclear anti-
gen (PCNA; Calbiochem) in both cytoplasmic and mito-
chondrial fractions. For cyt c release assays, aliquots from
mitochondrial preparations (equivalent to 20 mg of protein)
were incubated with or without narciclasine (10 mM) for 1 hour
at 37jC. Mitochondria were then spun down by 15 minutes
of centrifugation at 10,000g (4jC). The supernatants and pel-
lets of different incubations were then investigated for the
presence of cyt c by Western blot analysis.
DNA Fragmentation Assay
Cells (1.5  106) were treated with narciclasine (1 mM)
for different periods of time (0, 24, 48, and 72 hours). At
the end of each incubation period, intact chromatin was
separated from small apoptotic DNA fragments using the
method and reagents of the Suicide-Track DNA Ladder
Isolation kit (Calbiochem). Purified fragments were then re-
solved by standard agarose gel (1.5%) electrophoresis and
stained with 0.5 mg/ml ethidium bromide for visualization
under UV light.
Annexin V Assay
Control and treated cells were harvested by trypsiniza-
tion, resuspended in serum-containing medium to neutralize
trypsin, and washed twice with PBS. Cells were then resus-
pended in ice-cold 1 binding buffer (Sigma-Aldrich) at a
density of 106 cells/ml, and aliquots of 500 ml were stained
with 5 ml of Annexin V (Ann V)–FITC and 10 ml of propidium
iodide (PI; Sigma-Aldrich), as previously described [18].
Fluorescence was analyzed immediately on an Epics XL.MCL
flow cytometer (Beckman Coulter) equipped with a 488-nm
argon laser.
Western Blot Analysis and Immunoprecipitation
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM
Tris pH 8.0, 0.5% deoxycholic acid, and 1% NP-40) supple-
mented with protease inhibitors (Sigma-Aldrich). Protein con-
centration was quantified using the bicinchoninic acid protein
assay kit (Pierce; Perbio Science, Erembodegem, Belgium).
For each sample, equal amounts of proteins were subjected
to SDS-PAGE and transferred onto Polyscreen PVDF mem-
branes (NEN Life Science Products, PerkinElmer, Belgium).
Membranes were blocked and incubated with primary anti-
body overnight in Tris-buffered saline (TBS) with 0.2% Tween-
20 and 5% nonfat dry milk (or 5% bovine serum albumin,
as required). After three washes of 15 minutes in TBS con-
taining 0.2% Tween-20, blots were incubated for 1 hour with
peroxidase-conjugated secondary antibody (Pierce) and then
washed thrice in TBSwith 0.2% Tween-20, followed by chemi-
luminescent detection (Pierce). For immunoprecipitation of
death receptors, cells were lysed in lysis buffer containing
150 mM NaCl, 30 mM Tris (pH 7.5), 10% glycerol, 1% Triton
X-100, 5 mM EDTA, and protease inhibitors. Equal amounts
of proteins (600 mg) were immunoprecipitated overnight
with 2 mg of antibody. On the next day, protein-A Sepharose
beads (25 ml of a 50% vol/vol solution) were added. After
30 minutes of incubation, immunoprecipitates were washed
twice with 500 ml of lysis buffer and submitted to SDS-PAGE.
The primary antibodies used in the study and their sup-
pliers are as follows: Bid antibody (cat. no. 2002), caspase-8
(1C12; cat. no. 9746), caspase-9 (cat. no. 9502), caspase-3
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(3G2; cat. no. 9668), and caspase-10 (cat. no. 9752) anti-
bodies were obtained from Cell Signaling Technology (Dan-
vers, MA). The Bid antibody was used at a dilution of 1:500,
whereas caspases antibodies were all used at a dilution of
1:1000. Anti–cyt c antibody (cat. no. 556433) was obtained
from BD Bioscience Pharmingen (San Diego, CA) and was
used at a 1:500 dilution. Anti-Fas (C-20; cat. no. sc-715), anti–
death receptor 4 (DR4) (L-20; cat. no. 31344), and anti-GRP75
(C-19; cat. no. sc-1058) antibodies were obtained from Santa
Cruz Biotechnology and used at a dilution of 1:400. Anti-PCNA
(ab-1) antibody was fromCalbiochem and was used at a 1:400
dilution. Rabbit polyclonal anti–endonuclease G (Endo G)
(cat. no. ab9647), anti–apoptosis-inducing factor (AIF; cat.
no. ab1998), and rat anti-tubulin (ab6161) antibodies were ob-
tained fromAbcam (Cambridge, UK). The anti-tubulin antibody
was used at a dilution of 1:3000, whereas anti–Endo G and
anti-AIF antibodies were employed at a 1:500 dilution.
Results
Cancer Cells Are Markedly More Sensitive to the
Cytotoxic Effects of Narciclasine Than Normal Cells
The overall cytotoxic effects of narciclasine on a panel of
six human cancer and three normal human fibroblast cell
lines were assessed by MTT colorimetric assay. The data
illustrated in Figure 1, B and C, reveal that narciclasine dis-
played significantly higher cytotoxic effects on cancer cells
than on normal cells. The mean IC50 value (the concentration
that reduces by 50% the number of viable cells after 3 days of
treatment) calculated for the six human cancer cell lines was
30 nM. The corresponding mean IC50 value for the three
fibroblasts cell lines was 7.5 mM (Figure 1C), indicating their
markedly lower sensitivity to the cytotoxic effects of narci-
clasine than human cancer cells. The cytotoxic activity of nar-
ciclasine was similar in the six cancer cell lines investigated—
a feature consistent with National Cancer Institute data, which
reveal a mean IC50 value of 47 nM for the compound across a
panel of 60 cancer cell lines, including doxorubicin-resistant
cancer cells.
Narciclasine Induces Cancer Cell, But Not Normal
Cell, Apoptosis
The potential proapoptotic effects of narciclasine on Ccd-
25-Lu normal human fibroblasts and human cancer cells
(MCF-7 and MDA-MB-231 breast and PC-3 prostate can-
cers) were evaluated. In normal lung fibroblasts (Figure 2Aa)
treated with 1 mM narciclasine for 18 hours, no marked
morphologic changes were noted (Figure 2Ab). In sharp
contrast, when MCF-7 breast cancer cells (Figure 2Ac) un-
derwent the same treatment, dramatic morphologic changes
consistent with cell death were observed (Figure 2Ad ). Ccd-
25-Lu (Figure 2Ba), PC-3 (Figure 2Bb), MDA-MB-231 (Fig-
ure 2Bc), and MCF-7 (Figure 2Bd ) cells treated with 1 mM
narciclasine for up to 72 hours were analyzed for DNA
fragmentation. Internucleosomal DNA fragmentation is a
hallmark of apoptosis, with low-molecular-weight DNA frag-
ments forming a typical ladder after electrophoresis. Al-
though DNA laddering or smearing was not observed in
Ccd-25-Lu fibroblasts (Figure 2Ba), clear DNA laddering
was visible after only 24 hours of treatment of PC-3 (Fig-
ure 2Bb) and MDA-MB-231 (Figure 2Bc) cells and after
72 hours of treatment of MCF-7 cells (Figure 2Bd). The de-
lay observed in MCF-7 cells in DNA laddering is likely to be
due to the absence of caspase-3 in these cells [19]. DFF40/
CAD, the main endonuclease that drives DNA fragmentation
during apoptosis, forms an inactive complex in healthy cells
with its inhibitor DFF45/ICAD. The latter protein needs to
be cleaved in a caspase-dependent manner for DFF40 to
become active [20]. Caspase-3 is thought to be the main
caspase responsible for the processing of DFF45 [20].
Externalization of phosphatidyl serine, an early apoptotic
event that is the result of the flipping of plasma membrane
regions [21], was also investigated by means of double
labeling with Ann V and PI. The proportion of cells positive
for Ann V and negative for PI (early apoptotic compartment)
increased markedly in PC-3 prostate cancer (Figure 2Ca)
and MDA-MB-231 breast cancer (Figure 2Cb) cells treated
with 1 mM narciclasine for 24 hours. Only a modest increase
in the percentage of Ann V–positive to PI-negative cells (from
9.5% to 13.3%) was observed in Ccd-25-Lu fibroblasts after
24 hours of incubation with 1 mM narciclasine (Figure 2Cc).
Narciclasine Induces Mitochondrial Dysfunctions in Cancer
Cells: Loss of DWm and Release of Cyt c
Mitochondrial outer membrane permeabilization (MOMP)
is a crucial step in the apoptotic process and is often con-
comitant with a decrease in DWm as a direct consequence of
the loss of integrity in the outer mitochondrial membrane
(OMM) [22]. MOMP is lethal because it leads to the release
of diverse apoptotic effectors contained in the mitochondrial
transmembrane space and compromises mitochondrial en-
ergy metabolism [22]. JC-1 dye was used to measure DWm in
untreated and narciclasine-treated cells, with accumulation
of the dye into the mitochondria being directly dependent on
their DWm [14,15]. Once inside the mitochondria, the JC-1
dye forms aggregates that fluoresce bright red. In contrast,
the dye fluoresces green in the cytoplasm, where it remains
in a monomeric form [14,15]. An 18-hour incubation of MCF-
7 cells with 1 mM narciclasine resulted in a sharp decrease
(from 90% to 38%) in the percentage of cells displaying an
intact DWm, as analyzed by flow cytometry (Figure 3A). Simi-
lar results were obtained in MCF-7 cells treated with 100 nM
or 1 mM narciclasine for 24 hours (Figure 3B). A similar level
of decrease in DWm was also observed in PC-3 prostate car-
cinoma cells incubated with 1 mM narciclasine for 18 hours
(Figure 3C). No loss of DWm was observed after the same
treatment of normal Ccd-25-Lu lung fibroblasts (Figure 3D).
Given that the loss of DWm might be the consequence of
MOMP, these results prompted the determination of whether
apoptosis effectors such as cyt c were released into the cy-
toplasm. Accordingly, an analysis of mitochondrial and cyto-
plasmic fractions isolated from untreated and narciclasine-
treated (24 hours at 1 mM) MCF-7 cells was undertaken to
determine the levels of apoptosis effectors Endo G, AIF, and
cyt c. GRP75, predominantly localized in the mitochondrial
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matrix, was used as the process control [16,17]. Narciclasine
provoked a decrease in the level of mitochondrial fraction cyt
c matched by the corresponding appearance of cyt c in the
cytoplasm (Figure 4A). Thus, narciclasine is able to trigger
OMM permeabilization and the release of cyt c in MCF-7
breast cancer cells, consistent with the dramatic decrease
in DWm previously observed. Surprisingly, AIF and Endo G
were not released under the same conditions. A similar in-
vestigation was performed in PC-3 prostate carcinoma cells
untreated and treated with 100 nM and 1 mM narciclasine for
24 hours. PCNA, which is localized in both the nucleus and
the cytoplasm, was used as a process control [16,17]. PCNA
was, as expected, found essentially in cytosolic fraction
and was not readily detectable in mitochondrial fraction (Fig-
ure 4B). With or without narciclasine treatment, cyt c was
found to be retained in the mitochondria (Figure 4B). Similarly,
AIF was not released into the cytoplasm of PC-3 cells treated
with the compound for 24 hours (Figure 4C). The presence of
Endo G in PC-3 cells, as determined byWestern blot analysis,
could not be detected (Figure 4C). These results suggest that
PC-3 cell mitochondria are, in all likelihood, not involved in
the apoptotic process induced by narciclasine. Further testing
was undertaken to ascertain whether narciclasine was able to
trigger the release of cyt c from purified intact mitochondria.
Mitochondria were purified from PC-3 cells, and their integrity
was verified by Western blot analyses for GRP75, cyt c, and
PCNA (Figure 4D, upper panel ). Consistent with previous
results, no release of cyt c from the mitochondria into the
Figure 2. Narciclasine induces apoptosis in cancer cell lines. (A) Phase-contrast images of MCF-7 breast cancer cells (c and d) and Ccd-25-LU normal human
fibroblasts (a and b) untreated (a and c) or treated with 1 M narciclasine for 18 hours (b and d). (B) DNA ladder formation on the treatment of Ccd-25-LU normal
human fibroblast cells (a), PC-3 (b), MDA-MB-231 (c), and MCF-7 (d) cancer cells with narciclasine. Cells were treated for 0, 24, 48, and 72 hours with 1 M
narciclasine. At the end of the incubation, low-molecular-weight DNA fragments (< 50 kb) were extracted from an equal number of cells from each treatment and
subjected to electrophoresis on a 1.5% agarose gel. Lane M, different molecular weight markers (MWMs). The sizes of the different MWM DNA bands are indicated
on the left of each gel. (C) Externalization of phosphatidyl serine in PC-3 (a) and MDA-MB-231 (b) cells after treatment with 1 M narciclasine for 16 and 24 hours,
as well as in Ccd-25-LU human lung fibroblasts treated or not with 1 M of the compound for 24 hours (c). At the end of the incubation, cells were harvested and
labeled with Ann V–FITC and PI. The percentage of cells that were Ann V–positive and PI-negative (indicating early apoptotic compartments) was determined by
flow cytometry analysis.
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supernatant after their incubation with 10 mM narciclasine for
1 hour was determined (Figure 4D, lower panel ). This result
was also seen in MCF-7 cells where, again, no cyt c was
released from purified mitochondria after incubation with 0.1,
1, and 10 mM narciclasine for 1 hour (Figure 4E ). These data
collectively indicate that the involvement of themitochondria in
narciclasine-mediated apoptosis appears to be cancer cell
type–specific. There is also the suggestion that the mitochon-
dria are not the likely primary target of narciclasine and that
alternative pathways may be activated first. If this is the case,
then the mitochondria may only be involved in amplifying
apoptotic signals and only in certain cancer cell lines.
Narciclasine Induces the Activation of Caspase-8
and/or Caspase-10 in Human Prostate and Breast
Carcinoma Cells
A time course was performed after the treatment of PC-3
cells with 1 mM narciclasine, with the aim of determining the
activation of caspase-3, caspase-8, and caspase-9.
Caspase-3 was activated as shown by the disappearance
of procaspase-3 band (Figure 5A). Anti–caspase-3/clone
3G2 (Cell Signaling Technology) was the antibody used;
this antibody is expected to recognize both the procaspase
form and the large fragment (17/19 kDa). Unfortunately, in
our hands, only the decrease of the procaspase form was
observed, and we failed to detect this large processed
fragment. However, the intense internucleosomal DNA frag-
mentation observed in the PC-3 cell line after 24 hours of
treatment indicates that effector caspases are indeed ac-
tivated because DNA fragmentation relies on the activity of
effector caspases and, more precisely, on caspase-3. More-
over, we have also consistently observed in PC-3 cells
typical membrane blebbing after treatment with narciclasine
(data not shown). This morphologic change characteristic of
apoptosis also relies heavily on the activity of caspase-3. It
has been demonstrated that, in MCF-7 cells that are caspase-
3–deficient, such morphologic change does not occur fol-
lowing apoptosis induction [23]. In addition, reconstitution of
Figure 3. Involvement of mitochondria in apoptotic cell death induced by narciclasine. (A) JC-1 staining of MCF-7 cells either untreated (top panel) or treated with
1 M narciclasine for 18 hours (bottom panel): In each panel, the left histogram is a single-parameter analysis of the intensity of red fluorescence (specific to
mitochondria with intact DWm). The right panel is a dual-parameter analysis of red fluorescence (y-axis; FL-2) versus green cytoplasmic fluorescence (x-axis; FL-1).
(B) JC-1 staining of MCF-7 cells and visualization by fluorescence microscopy: MCF-7 cells were left untreated or treated with 100 nM or 1 M narciclasine for
24 hours. Images on the left (a, c, and e) depict the level of red fluorescence associated with the mitochondria. Images on the right (b, d, and f) are the
corresponding bright fields. (C) JC-1 staining performed on PC-3 cells either untreated (top panel) or treated with 1 M narciclasine for 18 hours (bottom panel). (D)
Effect of narciclasine on the mitochondrial transmembrane potential of Ccd-25-LU normal human fibroblasts. Cells were incubated for 18 hours in the presence or
in the absence of 1 M narciclasine. Histograms represent a single-parameter analysis of the intensity of red fluorescence in each condition.
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caspase-3 activity (following stable transfection of caspase-3
cDNA) restores the ability of MCF-7 cells to undergo mem-
brane blebbing [23].
Interestingly, no activation of caspase-9 was observed
(i.e., no loss and, thus, no cleavage of procaspase-9) (Fig-
ure 5A). This correlates well with the data in Figure 4B
indicating the absence of cyt c release after treatment with
100 or 1000 nM narciclasine. Indeed, in the mitochondrial
pathway of apoptosis, the release of cyt c into the cytoplasm
is a requirement for the formation of an active apoptosome
complex and the subsequent processing of caspase-9 [24].
After 16 hours of treatment with narciclasine, caspase-
8 is activated in PC-3 cells (Figure 5C). The disappearance
of bands corresponding to unprocessed procaspase-8 was
concomitant with an increase in processed caspase-8 (West-
ern blots p43/p41; Figure 5C). These results suggest that
caspase-8 itself activates caspase-3 in PC-3 prostate can-
cer cells. The data in Figure 5B indicate that anti–caspase-
3 antibody is specific for the expected protein. Indeed,
no band was detected in MCF-7 cells that do not express
caspase-3 [25].
Caspase-8 and caspase-10 are the initiator caspases
of the death receptor pathway. On activation of the death
receptor, these caspases are recruited to death-inducing
signaling complex (DISC), a protein complex that binds to
the receptor whose major function is to permit the proteolytic
autoactivation of caspase-8 and caspase-10 [26]. Further
investigations in PC-3, MCF-7, and MDA-MB-231 cancer
cells revealed that 16 hours after treatment with 1 mM narci-
clasine, caspase-8, but not caspase-10, was activated in
Figure 4. Narciclasine induces the release of cyt c in MCF-7 but not in PC-3 cells. (A) Release of mitochondrial apoptosis effectors in MCF-7 cells untreated
or treated with 1 M narciclasine for 24 hours: At the end of the incubation period, cells were fractionated as described in the Materials and Methods section. The
level of AIF, Endo G, and cyt c was determined by Western blot analysis in both cytosolic and mitochondrial fractions. (B) Analysis of cyt c release from PC-3 cells
left untreated or treated with 100 nM or 1 M narciclasine for 24 hours. Mitochondrial (M) and cytosolic (C) fractions were then isolated. Shown is an analysis of
the levels of PCNA and cyt c in each fraction by Western blot analysis. (C) Release of AIF and Endo G in PC-3 cells left untreated or treated with 1 M narciclasine
for 24 hours. The level of AIF and Endo G was determined by Western blot analysis in both cytoplasmic and mitochondrial fractions. (D) Analysis of cyt c release
induced by narciclasine in intact mitochondria purified from untreated PC-3 cells. Top panel: Western blots for GRP75, cyt c, and PCNA were performed to verify
the integrity of the mitochondria. Bottom panel: Mitochondria were incubated with solvent alone (Ctrl) or with 10 M narciclasine (Narc) for 1 hour at 37jC. At
the end of the incubation, the mitochondria were pelleted by centrifugation at 10,000g. The level of cyt c was measured by Western blot analysis in both
supernatants (released cyt c) and pellets (mitochondria). (E) Mitochondria isolated from MCF-7 cells were incubated with either solvent alone or increasing
concentrations of narciclasine (0.1, 1, and 10 M) for 1 hour at 37jC. The level of cyt c was determined by Western blot analysis in pellets (P) and supernatants
(S) of different incubations.
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both PC-3 and MCF-7 cells, whereas in MDA-MB-231 cells,
both caspases were found to be activated (Figure 5C).
Procaspase-10 bands for MCF-7 could be too thick to see
the decrease, but additional experiments confirmed the
absence of caspase-10 activation in both PC-3 and MCF-7
cells (data not shown).
These data suggest a possible involvement of the death
receptor pathway of apoptosis in the action of narciclasine.
Following the formation of DISC, this apoptosis pathway
involves, depending on the cell line, direct activation of
effector caspases by the initiators caspase-8 and caspase-
10 or, alternatively, it triggers the release of mitochondrial
apoptosis effectors through the processing of Bid into an
active truncated form (tBid) capable of inducing the perme-
abilization of the OMM. Indeed, MCF-7 cells treated with
1 mM narciclasine for up to 48 hours provoke the processing
of Bid (Figure 5D), which correlates well with the release
of cyt c previously observed (Figure 4A). Furthermore, it
was found that caspase-9 under the same incubation con-
ditions was also activated in MCF-7 cells—an activation that
largely depends on the release of cyt c (Figure 5D).
Narciclasine Induces the Formation of Fas and DR4
DISC, Leading to the Recruitment of Caspase-8
The possible recruitment of caspase-8 by death receptors
was investigated. PC-3 prostate cancer cells were left un-
treated or treated with 1 mMnarciclasine for 6 hours, and then
immunoprecipitation was performed on cell lysates using
anti-FAS, anti-DR4, anti-DR5, and anti-TNFR1 antibodies.
Subsequent Western blot analysis revealed that caspase-
8 was recruited by the death receptors FAS and DR4. In
narciclasine-treated cells but not in untreated cells, processed
caspase-8 (p43/p41) was found to exist in a complex with
both FAS and DR4, indicating the formation of DISC at the
level of these two receptors (Figure 6A). Straight Western
blots for caspase-8, FAS, DR4, and tubulin confirmed that
caspase-8 was already processed after 6 hours of treatment
and that an equal amount of protein had been used in different
immunoprecipitations (Figure 6A). In contrast, no recruitment
of caspase-8 by DR5 and TNFR1was found (data not shown).
Corresponding experiments performed in MCF-7 breast can-
cer cells and Ccd-25-Lu normal lung fibroblasts (Figure 6, B
and C) revealed the recruitment of caspase-8 by FAS and
DR4 in MCF-7 cells (Figure 6B)—although weaker than that
observed in PC-3 cells—but no recruitment in Ccd-25-Lu lung
fibroblasts (Figure 6C).
Discussion
Our results indicate that narciclasine shows potent in vitro
cytotoxic activity against all the six cancer cell lines investi-
gated. In contrast, normal human lung fibroblasts appear to
Figure 5. Narciclasine activates caspase-8 and/or caspase-10 in human prostate and breast cancer cells. (A) Activation of caspase-3, but not caspase-9, in PC-3
cells treated with 1 M narciclasine for 0, 16, and 24 hours. (B) Process control for the specificity of the anti –caspase-3 antibody used in this study. This was
confirmed by the nondetection of procaspase-3 or caspase-3 in MCF-7 cells, a cancer cell line that is known not to express caspase-3. (C) Activation of caspase-8
and caspase-10 in PC-3, MCF-7, and MDA-MB-231 cells. Cells were treated with 1 M narciclasine for 0, 16, 24, and 48 hours. (D) Processing of Bid and activation
of caspase-9 in MCF-7 cells treated with 1 M narciclasine for 0, 16, 24, and 48 hours.
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be markedly less sensitive to the molecule, with a mean
cytotoxic IC50 value of 7.5 mM compared to 30 nM for the
cancer cell lines. Additionally, based on comparative eval-
uations assessing morphologic changes, following inter-
nucleosomal DNA fragmentation or the externalization of
phosphatidyl serine in normal fibroblasts and human cancer
cells, the proapoptotic effects of narciclasine at concentra-
tions of up to 1 mM were confined to cancer cells. These
results collectively emphasize the marked selectivity of narci-
clasine for cancer cells.
Narciclasine indeed causes internucleosomal DNA frag-
mentation and flipping of phosphatidyl serine (hallmarks of
apoptotic processes) in a manner similar to that previously
reported for pancratistatin, a close structural analog (Figure 1A).
McLachlan et al. [11] reported that pancratistatin triggers
marked apoptosis in neuroblastoma cell populations, accom-
panied by the disruption of DWm, DNA fragmentation, and
increased reactive oxygen species production [11]. To un-
derstand the mechanism by which narciclasine induces
apoptosis, the role of the mitochondria was evaluated. The
mitochondria contain in their transmembrane space a variety
of proapoptotic effectors such as cyt c [27], AIF [28], Smac/
Diablo [29,30], Endo G [31], and Htra2/Omni [32], as well
as several procaspases [33]. During apoptosis, these pro-
teins are released from the transmembrane space into the
cytoplasm on MOMP. In MCF-7 cells, an 18-hour incubation
with 1 mM narciclasine leads to a severe decrease in DWm.
Cyt c was also released from the mitochondria into the cyto-
plasm, indicating that narciclasine causes a loss of integrity
of the OMM. In PC-3 prostate carcinoma cells, although
a decrease in DWm was observed, the magnitude of the
decrease was reduced compared to that in MCF-7 cells. In
addition, no release of cyt c was observed after 24 hours of
incubation with narciclasine. Furthermore, when narciclasine
was incubated at concentrations of up to 10 mM with intact
mitochondria purified from MCF-7 or PC-3 cells, it failed
to trigger MOMP or the release of cyt c. Collectively, these
data suggest that the involvement of the mitochondria in
Figure 6. Activation of the death receptors FAS and DR4 by narciclasine. (A) PC-3 cells were left untreated or treated with 1 M narciclasine for 6 hours. At the end
of the incubation, protein extracts were prepared and immunoprecipitated with anti-FAS (left panel) or anti-DR4 (right panel) antibody. After the isolation of the
protein complex and electrophoresis, Western blot analysis of caspase-8 was performed. The input gel (bottom panel) shows straight Western blots for caspase-8,
FAS, DR4, and tubulin aimed to verify whether an equal amount of material was used in each immunoprecipitation. (B) Immunoprecipitation of the DR4 and FAS
receptors followed by detection of caspase-8 in MCF-7 cells untreated or treated with 1 M narciclasine for 6 hours. (C) Immunoprecipitation of the DR4 and FAS
receptors followed by detection of caspase-8 in Ccd-25-Lu normal human lung fibroblasts untreated or treated with 1 M narciclasine for 6 hours.
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narciclasine-mediated apoptosis is cell type–specific and
not necessarily the result of a direct action of the molecule
on these organelles. Indeed, there exist two main path-
ways of apoptosis: the mitochondrial pathway and the death
receptor pathway, also called the extrinsic pathway [34].
Death receptors belong to the tumor necrosis factor (TNF)
superfamily of receptors and share in common a distinctive
cytoplasmic domain called the death domain. This group of
receptors includes FAS and DR3, which interact with Fas-L,
DR4, and KILLER/DR5 that binds TNF-related apoptosis-
inducing ligand (TRAIL), as well as TNFR1 and DR6 [34].
The death receptor pathway of apoptosis has been repeat-
edly involved in chemotherapy-induced cell death. This has
been well described for the antitumor molecule etoposide,
which largely relies on this pathway to induce apoptosis [34].
DNA-damaging agents can sensitize cells to this apoptosis
pathway by modifying the expression of genes that regulate
it. For instance, DR4, DR5, and FAS are p53-responsive
genes [35,36]. In the three tumor cell lines in which it was
examined in this study (MCF-7, PC-3, and MDA-MB-231),
activation of the initiator caspases of the death receptor path-
way, namely, caspase-8 and/or caspase-10, was observed.
Activation of death receptors leads to the formation of DISC.
The adaptor FADD binds to the death domain (DD) in the
cytoplasmic portion of the receptor and subsequently recruits
caspase-8 and caspase-10. These initiator caspases then un-
dergo proteolytic autoactivation and are eventually released
from DISC [34]. Our data reveal that narciclasine treatment
of PC-3 prostate and MCF-7 breast carcinoma cells results
in the activation of the death receptors FAS and DR4. By
immunoprecipitation, it was possible to show the recruitment
and activation of caspase-8 at both receptors. With regard
to FAS, two types of cells can be distinguished (Figure 7).
In type I cells, a high amount of procaspase-8 is recruited to
DISC, leading to the activation of caspase-8 at a level suf-
ficiently high to directly initiate a downstream caspase cas-
cade (Figure 7) [34]. However, in type II cells, the recruitment
and activation of caspase-8 at DISC, as well as the amount
of formed DISC, are lower and insufficient to trigger the cas-
pase cascade on its own (Figure 7). In type II cells, the
apoptotic process requires a mitochondria-dependent am-
plification step (Figure 7) [34]. Thus, it appears that PC-3
prostate carcinoma cells behave on treatment with narcicla-
sine-like type I cells: A marked recruitment of caspase-8 at
FAS DISC was observed, concomitant to the processing of
caspase-3 (Figure 7). In addition, no release of proapoptotic
mitochondrial effectors or activation of caspase-9, whose pro-
cessing is largely dependent on the release of cyt c, was ob-
served. In contrast, narciclasine-induced apoptosis clearly
involved the mitochondria in MCF-7 cells. Bid cleavage was
also observed together with the release of cyt c and the sub-
sequent activation of caspase-9, showing that MCF-7 cells
react like type II cells in response to narciclasine (Figure 7).
It should be noted also that TRAIL induces programmed
cell death in many tumor cells, but not in most normal cells,
including normal human lung fibroblasts [37,38]. In addition,
normal human lung fibroblasts do not undergo apoptosis in
response to TNF-a or an agonistic anti-Fas antibody [39].
In conclusion, Amaryllidaceae isocarbostyrils, such as
narciclasine and pancratistatin, appear to be an attractive
family of molecules with respect to cancer chemotherapy.
Both pancratistatin [11] and narciclasine have potent in vitro
anticancer activity and good selectivity, with tumor cells
being markedly more sensitive than normal cells. Our pres-
ent report emphasizes the role of the death receptors DR4
and FAS in narciclasine-mediated apoptosis.
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